Clinical Trial Update: The Efficacy of PD-1 Antibody Sintilimab on Early-stage Multiple Primary Lung Cancer With Ground Glass Density. [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the efficacy of the PD-1 antibody sintilimab in early-stage multiple primary lung cancers with ground-glass nodules.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer
• Multiple Primary Lung Cancers

Drugs mentioned

• Sintilimab (sintilimab)

Snippet

Sponsor: The First Affiliated Hospital of Guangzhou Medical University | Conditions: Multiple Primary Lung Cancers | Phase 2 | Status: UNKNOWN